Results 121 to 130 of about 87,310 (290)
Project Rulison final operational radioactivity report production tests
R Gotchy
openalex +2 more sources
RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha+10 more
wiley +1 more source
Comparing conventional and Bayesian workflows for clinical outcome prediction modelling with an exemplar cohort study of severe COVID-19 infection incorporating clinical biomarker test results. [PDF]
Sullivan B+14 more
europepmc +1 more source
Single‐cell transcriptomics of prostate cancer patient‐derived xenografts reveals distinct features of neuroendocrine (NE) subtypes. Tumours with focal NE differentiation (NED) share transcriptional programmes with adenocarcinoma, differing from large and small cell neuroendocrine prostate cancer (NEPC). Our work defines the molecular landscape of NEPC,
Rosalia Quezada Urban+12 more
wiley +1 more source
Chip-to-chip photonic quantum teleportation over optical fibers of 12.3 km. [PDF]
Liu D+11 more
europepmc +1 more source
Microglia (BV2) and IL‐4‐treated BMDMs promote astrocytoma clustering and inhibit tumor growth, not shown in other macrophage cells. In vivo, microglial co‐implantation enhances CD8+ T cell infiltration, elevates Granzyme B, lowers circulating MDSCs, and extends survival only in immune‐competent mice, but not in immune‐deficient mice.
Tzu‐Chieh Sun+5 more
wiley +1 more source
Evaluating Children's Drawings as a Means of Expression in Children with Chronic Diseases. [PDF]
Manomenidis G+7 more
europepmc +1 more source
The Relationship Between Trait and State Anxiety and a Projective Personality Test.
Harold Coco
openalex +2 more sources
Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts+8 more
wiley +1 more source